TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Glutamine | Arm Label: b; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: c; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: d; Type: PLACEBO_COMPARATOR; Interventions: Drug: glycine | Arm Label: e; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: f; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Intervention Type: DRUG; Name: Glutamine; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): b, c, e, f | Intervention Type: DRUG; Name: glycine; Assigned to Arm(s): d | Intervention Type: DRUG; Name: zinc; Assigned to Arm(s): b, c, e, f
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vitamin A | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vitamin A | Intervention Type: BIOLOGICAL; Name: Vitamin A; Assigned to Arm(s): 1, 2
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU); Assigned to Arm(s): Placebo, Vitamin A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Center Randomized Clinical Trial of the Effects of Acetylcysteine in the Prevention of Postoperative Renal Failure
Brief Summary: The purpose of this study is to determine if Acetylcysteine is effective in preventing renal failure associated with cardiac surgery


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: epoetinum | Intervention Type: DRUG; Name: epoetinum; Assigned to Arm(s): 2
B: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo
C: Arm Label: CytoSorb; Type: EXPERIMENTAL; Interventions: Device: CytoSorb | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: CytoSorb; Assigned to Arm(s): CytoSorb
D: Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Center Randomized Clinical Trial of the Effects of Acetylcysteine in the Prevention of Postoperative Renal Failure
Brief Summary: The purpose of this study is to determine if Acetylcysteine is effective in preventing renal failure associated with cardiac surgery


Options:
A: Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: N-acetylcysteine plus deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine and deferoxamine | Intervention Type: DRUG; Name: N-acetylcysteine and deferoxamine; Assigned to Arm(s): N-acetylcysteine plus deferoxamine
C: Intervention Type: DRUG; Name: Sodium Bicarbonate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)
Brief Summary: To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.


Options:
A: Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
B: Arm Label: ABT-335 plus rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335 plus rosuvastatin | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: ABT-335 plus rosuvastatin; Assigned to Arm(s): ABT-335 plus rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diet+pravastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)
Brief Summary: To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.


Options:
A: Arm Label: Experimental: Rosuvastatin + enoxaparin arm; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin 20mg/d for 14days | Arm Label: enoxaparin only; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin only | Intervention Type: DRUG; Name: Rosuvastatin 20mg/d for 14days; Assigned to Arm(s): Experimental: Rosuvastatin + enoxaparin arm | Intervention Type: DRUG; Name: enoxaparin only; Assigned to Arm(s): enoxaparin only
B: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diet+pravastatin; Assigned to Arm(s): N/A
D: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)
Brief Summary: To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.


Options:
A: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diet+pravastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism
Brief Summary: The study is designed to assess the efficacy of treatment with divalproex sodium (DS) vs. placebo in childhood/adolescent autism fulfilling DSM-IV and Autism Diagnostic Interview (ADI) criteria. Currently, there are no FDA-approved treatments for this disorder, although behavioral and educational therapies and a variety of medications may play a role in the management of some autistic symptoms.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Divalproex Sodium; Type: EXPERIMENTAL; Interventions: Drug: Divalproex sodium | Intervention Type: DRUG; Name: Divalproex sodium; Assigned to Arm(s): Divalproex Sodium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone low dose | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Risperidone high dose | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone high dose; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidone low dose; Assigned to Arm(s): 001
C: Arm Label: Syntocinon (Oxytocin, product code RVG 03716); Type: EXPERIMENTAL; Interventions: Drug: Syntocinon (Oxytocin) | Arm Label: Placebo (Physiological water(sodium chloride (NaCl) solution)); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)) | Intervention Type: DRUG; Name: Syntocinon (Oxytocin); Assigned to Arm(s): Syntocinon (Oxytocin, product code RVG 03716) | Intervention Type: OTHER; Name: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)); Assigned to Arm(s): Placebo (Physiological water(sodium chloride (NaCl) solution))
D: Intervention Type: DRUG; Name: secretin, synthetic porcine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: secretin, biologically derived porcine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism
Brief Summary: The study is designed to assess the efficacy of treatment with divalproex sodium (DS) vs. placebo in childhood/adolescent autism fulfilling DSM-IV and Autism Diagnostic Interview (ADI) criteria. Currently, there are no FDA-approved treatments for this disorder, although behavioral and educational therapies and a variety of medications may play a role in the management of some autistic symptoms.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Divalproex Sodium; Type: EXPERIMENTAL; Interventions: Drug: Divalproex sodium | Intervention Type: DRUG; Name: Divalproex sodium; Assigned to Arm(s): Divalproex Sodium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Risperidone; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism
Brief Summary: The study is designed to assess the efficacy of treatment with divalproex sodium (DS) vs. placebo in childhood/adolescent autism fulfilling DSM-IV and Autism Diagnostic Interview (ADI) criteria. Currently, there are no FDA-approved treatments for this disorder, although behavioral and educational therapies and a variety of medications may play a role in the management of some autistic symptoms.


Options:
A: Intervention Type: DRUG; Name: Galantamine; Assigned to Arm(s): N/A
B: Arm Label: Syntocinon (Oxytocin, product code RVG 03716); Type: EXPERIMENTAL; Interventions: Drug: Syntocinon (Oxytocin) | Arm Label: Placebo (Physiological water(sodium chloride (NaCl) solution)); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)) | Intervention Type: DRUG; Name: Syntocinon (Oxytocin); Assigned to Arm(s): Syntocinon (Oxytocin, product code RVG 03716) | Intervention Type: OTHER; Name: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)); Assigned to Arm(s): Placebo (Physiological water(sodium chloride (NaCl) solution))
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine (Zyprexa) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: olanzapine (Zyprexa); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Divalproex Sodium; Type: EXPERIMENTAL; Interventions: Drug: Divalproex sodium | Intervention Type: DRUG; Name: Divalproex sodium; Assigned to Arm(s): Divalproex Sodium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Post-TBI Depression - A Randomized Clinical Trial
Brief Summary: Randomized clinical trial that compares the effects of cognitive behavioral therapy (CBT) and supportive psychotherapy for depression. Short- and long-term outcomes will be evaluated in terms of changes in mood (primarily depression and anxiety), participation in activities and life satisfaction.


Options:
A: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Scheduled telephone follow-up | Intervention Type: BEHAVIORAL; Name: Scheduled telephone follow-up; Assigned to Arm(s): 1
B: Arm Label: MBCT Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: MBCT for TBI | Arm Label: MBCT Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MBCT for TBI; Assigned to Arm(s): MBCT Intervention Group
C: Arm Label: Telephone-based CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Cognitive Behavioral Therapy | Arm Label: In-person CBT; Type: EXPERIMENTAL; Interventions: Behavioral: In-person Cognitive Behavioral Therapy | Arm Label: 3: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: In-person Cognitive Behavioral Therapy; Assigned to Arm(s): In-person CBT | Intervention Type: BEHAVIORAL; Name: Telephone Cognitive Behavioral Therapy; Assigned to Arm(s): Telephone-based CBT
D: Arm Label: Treatment Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy | Arm Label: Treatment Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): Treatment Arm 1 | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Treatment Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)
Brief Summary: This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with relapsing-remitting (RR) multiple sclerosis (MS).


Options:
A: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate
B: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Dimethyl Fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dimethyl fumarate, Drug: Sodium Chloride solution | Arm Label: Sodium Chloride solution; Type: SHAM_COMPARATOR; Interventions: Drug: Dimethyl fumarate, Drug: Sodium Chloride solution | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Dimethyl fumarate; Assigned to Arm(s): Dimethyl Fumarate, Sodium Chloride solution | Intervention Type: DRUG; Name: Sodium Chloride solution; Assigned to Arm(s): Dimethyl Fumarate, Sodium Chloride solution
C: Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab
D: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A